WO2007096596A3 - Use of il-8 for the treatment of crohn' s disease - Google Patents

Use of il-8 for the treatment of crohn' s disease Download PDF

Info

Publication number
WO2007096596A3
WO2007096596A3 PCT/GB2007/000577 GB2007000577W WO2007096596A3 WO 2007096596 A3 WO2007096596 A3 WO 2007096596A3 GB 2007000577 W GB2007000577 W GB 2007000577W WO 2007096596 A3 WO2007096596 A3 WO 2007096596A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
crohn
pro
subject
relates
Prior art date
Application number
PCT/GB2007/000577
Other languages
French (fr)
Other versions
WO2007096596A2 (en
Inventor
Anthony Walter Segal
Daniel Joseph Benjamin Marks
Original Assignee
Ucl Business Plc
Anthony Walter Segal
Daniel Joseph Benjamin Marks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc, Anthony Walter Segal, Daniel Joseph Benjamin Marks filed Critical Ucl Business Plc
Publication of WO2007096596A2 publication Critical patent/WO2007096596A2/en
Publication of WO2007096596A3 publication Critical patent/WO2007096596A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to use of a pro-inflammatory agent such as IL-8 or muramyl dipeptide (MDP) for the manufacture of a medicament for Crohn's disease. Preferably the pro-inflammatory agent is a neutrophil chemoattractant. Preferably the pro- inflammatory agent is EL-8. The invention also relates to a method of treating Crohn's disease in a subject, said method comprising administering to said subject an effective amount of a pro-inflammatory agent such as IL-8, and to IL-8 for use in the treatment of Crohn's disease. The invention also relates to products comprising IL-8 for topical treatment. The invention also relates to methods for determining the responsiveness of a subject to MDP comprising determining the CARD15 genotype of the subject.
PCT/GB2007/000577 2006-02-21 2007-02-20 Use of il-8 for the treatment of crohn' s disease WO2007096596A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0603427.6 2006-02-21
GBGB0603427.6A GB0603427D0 (en) 2006-02-21 2006-02-21 IL-8 Therapy

Publications (2)

Publication Number Publication Date
WO2007096596A2 WO2007096596A2 (en) 2007-08-30
WO2007096596A3 true WO2007096596A3 (en) 2007-10-18

Family

ID=36178447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000577 WO2007096596A2 (en) 2006-02-21 2007-02-20 Use of il-8 for the treatment of crohn' s disease

Country Status (2)

Country Link
GB (1) GB0603427D0 (en)
WO (1) WO2007096596A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070564A1 (en) * 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
EP2620156B1 (en) * 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
JP2023507885A (en) * 2019-11-12 2023-02-28 オーチャード セラピューティクス（ヨーロッパ）リミテッド Compositions and methods for treating or preventing Crohn's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
WO2000057902A1 (en) * 1999-03-25 2000-10-05 Technion Research And Development Foundation Ltd. Method and pharmaceutical composition for wound healing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
WO2000057902A1 (en) * 1999-03-25 2000-10-05 Technion Research And Development Foundation Ltd. Method and pharmaceutical composition for wound healing

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRANDT E ET AL: "Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD)", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 122, no. 2, November 2000 (2000-11-01), pages 180 - 185, XP002440694, ISSN: 0009-9104 *
LI JING ET AL: "Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations", HUMAN MOLECULAR GENETICS, vol. 13, no. 16, 15 August 2004 (2004-08-15), pages 1715 - 1725, XP002440692, ISSN: 0964-6906 *
MARKS DANIEL J B ET AL: "Failure of the acute inflammatory response in Crohn's disease: The influence of CARD15", GASTROENTEROLOGY, vol. 126, no. 4, Suppl. 2, April 2004 (2004-04-01), & DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, pages A151, XP002440693, ISSN: 0016-5085 *
MARKS ET AL: "Defective acute inflammation in Crohn's disease: a clinical investigation", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 367, no. 9511, 25 February 2006 (2006-02-25), pages 668 - 678, XP005305773, ISSN: 0140-6736 *
PHILPOTT DANA J ET AL: "Towards an understanding of the role of NOD2/CARD15 in the pathogenesis of Crohn's disease.", BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY JUN 2004, vol. 18, no. 3, June 2004 (2004-06-01), pages 555 - 568, XP002440691, ISSN: 1521-6918 *
VAN HEEL D A ET AL: "Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9473, 21 May 2005 (2005-05-21), pages 1794 - 1796, XP004912848, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
GB0603427D0 (en) 2006-04-05
WO2007096596A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2005099680A3 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
PT1594833E (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2004045507A3 (en) Anti-angiogenic uses of il-6 antagonists
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
EP1744162A4 (en) Cancer diagnosis and treatment using anti-robo1 antibody
WO2007096596A3 (en) Use of il-8 for the treatment of crohn' s disease
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
WO2007120720A3 (en) Uses and compositions for treatment of crohn's disease
WO2006058298A3 (en) A method of administering anti-angiogenic agents and a method of treating disease using same
WO2002087503A3 (en) Compositions and methods for treating colorectal polyps and cancer
CA2480429A1 (en) Novel therapeutical use of agonist ligands specific to g2a receptor
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2006044107A3 (en) Method of treating human preeclampsia employing resibufagenin
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003272189A1 (en) Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07712753

Country of ref document: EP

Kind code of ref document: A2